Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies.

Angelo BellinviaMaria Grazia ApreaEmilio PortaccioLuisa PastòLorenzo RazzoliniMattia FondericoIlaria AddazioMatteo BettiMaria Pia Amato

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2022)

Our study confirms that COVID-19 vaccination in MS patient is safe and effective in preventing symptomatic COVID-19 and should be recommended to all patients. Moreover, we suggest a possible role of hypogammaglobulinemia in reducing Ab response in patients treated with antiCD20 therapies.

Keyphrases

sars cov
coronavirus disease
end stage renal disease
mass spectrometry
multiple sclerosis
respiratory syndrome coronavirus
ms ms
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
patient reported outcomes